Resources

 

Fact Sheets

CSRxP Biosimilar Competition Fact Sheet

Big Pharma deploys a full suite of tactics designed to game the U.S. patent system — enabling brand name drug companies to extend monopolies over their biggest money-makers. The pharmaceutical industry’s egregious abuse of the patent system is a root cause of high prescription drug prices because it enables Big Pharma to repeatedly hike prices on existing drugs,

05-2-2024

FACT SHEET: BIG PHARMA BRINGS INSULIN PRICE-GOUGING PLAYBOOK TO BLOCKBUSTER WEIGHT LOSS DRUGS

As 2023 comes to a close, one of the biggest stories in the drug pricing space this year has been a new “gold rush” for Big Pharma around weight loss drugs. Several Big Pharma companies have launched new products in this space or received approval to prescribe older products for this new category. It’s increasingly

12-13-2023

Fact Sheet: Patent Abuse

Big Pharma has a long history of price-gouging American patients through tactics designed to game the U.S. patent system and block competition from more affordable alternatives — enabling Big Pharma to maintain monopolies over their biggest money-makers. The pharmaceutical industry’s egregious abuse of the patent system is a root cause of high prescription drug prices because it enables Big

09-21-2023

CSRxP Innovation Fact Sheet

For far too long Big Pharma has used the excuse that research and development (R&D) costs justify out-of-control prescription drug prices and that solutions to lower prices threaten innovation into new breakthroughs. These tired arguments, which Big Pharma wields like a shield to protect the industry’s anti-competitive and price-hiking practices, simply don’t hold up to

09-19-2023

DOSE OF REALITY: LIST PRICE TRANSPARENCY WILL HELP HOLD BIG PHARMA ACCOUNTABLE AND LOWER PRESCRIPTION DRUG PRICES FOR PATIENTS

Congress Should Advance Bipartisan, Market-Based Measures to Increase Transparency to Shine a Light on Brand Name Drug Companies’ Egregious Price Hikes and Launch Prices  Big Pharma companies are responsible for setting and increasing prices on the prescription drugs in their portfolio. Solutions that boost list price transparency can shine a light on the industry’s worst

04-27-2023

Document: Morning Consult January 2023

The Campaign for Sustainable Rx Pricing (CSRxP) released the results of a national survey conducted by Morning Consult today that found American voters overwhelmingly reject Big Pharma’s blame game and want policymakers to advance market-based solutions to hold brand name drug companies accountable.

01-24-2023

Fact Sheet: Innovation 2022

SECOND OPINION: DEBUNKING BIG PHARMA’S BOGUS INNOVATION RHETORIC Brand Name Drug Companies Claim Lowering Rx Prices Will Undercut R&D — The Facts Disagree For far too long Big Pharma has used the excuse that research and development (R&D) costs justify out-of-control prescription drug prices and that solutions to lower prices threaten innovation into new breakthroughs.

03-14-2022

Fact Sheet: Morning Consult Prescription Drug Pricing Poll

AMERICANS FACE FINANCIAL CHALLENGES AS A RESULT OF INCREASING DRUG PRICES More than one in four American voters reported (26%) that they or a family member had 26% financial difficulty affording a prescribed medication in the last 12 months. VOTERS OVERWHELMINGLY WANT CONGRESS TO ACT LACK OF ACTION WILL IMPACT VOTE IN NEXT ELECTION Four

09-14-2021

Fact Sheet: Cancer Drug Prices

THE PROBLEM: A CRISIS OF AFFORDABILITY The out-of-control prices set by Big Pharma on prescription drugs used to treat cancer have created a crisis of affordability — and placed breakthrough treatments out-of-reach for too many American patients. Patients and families should never have to face heart-wrenching choices between paying for their cancer treatment or for

04-15-2021

Drug Pricing Overview – 117th Congress

02-1-2021

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.